Articles related to Cardiology

The oral suspension formulation was developed for patients who have difficulty swallowing the tablet form of the PDE5 inhibitor.

In this commentary, the editor-in-chief of CCJM considers what is known, and what is still mystery about how the heart and kidneys are modified during chronic heart failure, and discusses how much of our therapy remains empiric and experience-based.

Up to this point, individuals with non-alcoholic fatty liver disease (NAFLD) and a normal BMI have often been overlooked. It was assumed their normal BMI equated to a lower risk of more serious conditions than those who are overweight or obese. These findings indicate that lean patients with NAFLD are 50% more likely to have a CVA compared with overweight patients, and 10 to 30% more likely to experience CVD.

Seven-hundred patients with left ventricular ejection fraction (LVEF) of 35% or less, extensive coronary artery disease amenable to PCI, and demonstrable myocardial viability were randomly assigned to PCI plus optimal medical therapy vs. optimal medical therapy alone. At 6 months, the LVEF was similar between the two groups.

The IV-equivalent formulation is indicated for the treatment of congestion due to fluid overload in people with NYHA class II/III chronic heart failure and may offer a substantial change in the management of the condition.

Atrial fibrillation (AF) can be managed by either a rate control or a rhythm control strategy. Data as to whether rate control or a rhythm control provides better clinical outcomes have been mixed. Therefore, even if direct evidence from randomized clinical trials is lacking in many types of patients, given the unpredictable long-term adverse effects of atrial fibrillation, rhythm control is generally the goal.